EUVIMEDEUVIMED entdecken
Open Access

First Experiences of Pilot Clinical Studies on Boron Neutron Capture Therapy for Recurrent Gastrointestinal Cancers Using an Intravenous Injection of 10 BPA

Hironobu Yanagie, Syoji Maruyama, Kazuyuki Oyama, Yasuo Ono, Shinichi Kuroyama, Yasumasa Nonaka, Ryo Hatae, Yoshitaka Furuya, Minoru Suzuki, Shin-Ichiro Masunaga, Yoshinori Sakurai, Natsuko Kondo und 5 weitere

In Vivo · 2025

DOI: 10.21873/invivo.13948 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Hironobu Yanagie und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Shin-Yamate Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan; h.yanagie@gmail.com. Hauptthemen laut MEDLINE: Boron Neutron Capture Therapy, Gastrointestinal Neoplasms, Neoplasm Recurrence, Local, Boron Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Boron neutron capture therapy (BNCT) is a novel treatment that induces targeted tumor cell damage through the selective accumulation of 10B compounds in cancer cells followed by the production of alpha and lithium particles using thermal neutron irradiation. Despite its potential, clinical applications of BNCT for recurrent gastrointestinal cancers remain limited. This study presents the first pilot clinical evaluation of BNCT using intravenous boronophenylalanine (10BPA) for such cancers. CASE REPORTS: Four patients with recurrent gastrointestinal cancers were enrolled in this phase I-II clinical study. All had tumors refractory to standard treatments, including surgery, chemotherapy, and radiotherapy. BNCT was performed using thermal neutron irradiation at Kyoto University Research Reactor. 10BPA was administered intravenously at 400 mg/kg, and no severe adverse effects were observed. Tumor responses varied, with one patient achieving partial response and three demonstrating stable disease at three months post-treatment. Notably, BNCT alleviated cancer-related symptoms, such as pain and nerve compression, improving patients' quality of life. Dosimetric evaluations confirmed effective tumor doses with acceptable exposure to surrounding normal tissues. CONCLUSION: BNCT is a promising modality for recurrent gastrointestinal cancers, offering symptom relief and potential antitumor effects. Its safety and feasibility were demonstrated in this study. Future research should explore fractionated BNCT and combination therapies with immunotherapy or targeted agents to enhance efficacy further.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Boron Neutron Capture TherapyGastrointestinal NeoplasmsNeoplasm Recurrence, LocalBoron CompoundsPhenylalanineHumansMalePilot ProjectsMiddle AgedFemaleAgedTreatment OutcomeInjections, Intravenous

Stichwörter der Autor:innen

Alpha particleBoron neutron capture therapy (BNCT)Boronophenylalanine (10BPA)atomic reactorrecurrent gastrointestinal cancersthermal neutron

Substanzen

Boron CompoundsPhenylalanine

Autor:innen und Institutionen

  • Department of Surgery, Shin-Yamate Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan; h.yanagie@gmail.com.
  • Department of Gastrointestinal Surgery, Keiaikai Kojin Hospital, Iwate, Japan.
  • Institute of Engineering Innovation, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.
  • Cooperative Unit of Medicine & Engineering, The University of Tokyo Hospital, Tokyo, Japan.
  • Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.
  • Department of Surgery, Shin-Yamate Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Zitieren

APA

Yanagie, H., Maruyama, S., Oyama, K., Ono, Y., Kuroyama, S., Nonaka, Y., Hatae, R., Furuya, Y., Suzuki, M., Masunaga, S. I., Sakurai, Y., Kondo, N., Tanaka, H., Maruhashi, A., Ono, K., Sugihara, T., & Takahashi, H. (2025). First Experiences of Pilot Clinical Studies on Boron Neutron Capture Therapy for Recurrent Gastrointestinal Cancers Using an Intravenous Injection of 10 BPA. In Vivo. https://doi.org/10.21873/invivo.13948

Vancouver

Yanagie H, Maruyama S, Oyama K, Ono Y, Kuroyama S, Nonaka Y, et al. First Experiences of Pilot Clinical Studies on Boron Neutron Capture Therapy for Recurrent Gastrointestinal Cancers Using an Intravenous Injection of 10 BPA. In Vivo. 2025. doi:10.21873/invivo.13948

BibTeX
@article{Yanagie2025,
  author = {Yanagie, Hironobu and Maruyama, Syoji and Oyama, Kazuyuki and Ono, Yasuo and Kuroyama, Shinichi and Nonaka, Yasumasa and Hatae, Ryo and Furuya, Yoshitaka and Suzuki, Minoru and Masunaga, Shin-Ichiro and Sakurai, Yoshinori and Kondo, Natsuko and Tanaka, Hiroki and Maruhashi, Akira and Ono, Koji and Sugihara, Takumichi and Takahashi, Hiroyuki},
  title = {First Experiences of Pilot Clinical Studies on Boron Neutron Capture Therapy for Recurrent Gastrointestinal Cancers Using an Intravenous Injection of 10 BPA},
  journal = {In Vivo},
  year = {2025},
  doi = {10.21873/invivo.13948}
}
Kostenlos starten →